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Cerebral white matter injury (WMI) persistently disrupts myelin regeneration by oligodendrocyte progenitor cells (OPCs).
We identified a specific bioactive hyaluronan fragment (bHAf) that downregulates myelin gene expression and chronically
blocks OPC maturation and myelination via a tolerance-like mechanism that dysregulates pro-myelination signaling via
AKT. Desensitization of AKT occurs via TLR4 but not TLR2 or CD44. OPC differentiation was selectively blocked by bHAf in a
maturation-dependent fashion at the late OPC (preOL) stage by a noncanonical TLR4/TRIF pathway that induced persistent
activation of the FoxO3 transcription factor downstream of AKT. Activated FoxO3 selectively localized to oligodendrocyte
lineage cells in white matter lesions from human preterm neonates and adults with multiple sclerosis. FoxO3 constraint
of OPC maturation was bHAf dependent, and involved interactions at the FoxO3 and MBP promoters with the chromatin
remodeling factor Brg1 and the transcription factor Olig2, which regulate OPC differentiation. WMI has adapted an immune
tolerance–like mechanism whereby persistent engagement of TLR4 by bHAf promotes an OPC niche at the expense of
myelination by engaging a FoxO3 signaling pathway that chronically constrains OPC differentiation.

Introduction

Immune tolerance (IT) is a transient state in cells of the innate
immune system where repeated exposure to pathogen-associated molecular patterns (PAMPs) or damage-associated molecular
patterns (DAMPs) renders cells unresponsive to further PAMP/
DAMP exposure (1, 2). Removal of the PAMP/DAMP recalibrates
the system with restoration of immune responses. An initial excessive inflammatory response via TLRs can induce a tolerant state
(1). IT has evolved to prevent excessive immune system mediated
self-injury in response to infection, inflammation, or tissue injury.
However, some bacteria exploit IT to evade immune system surveillance. Repeated exposure to bacterial endotoxin chronically
suppresses host proinflammatory immune responses, which causes bacteria to overwhelm and kill the host.
In the central nervous system, the megadalton form of hyaluronan (MDa HA) is a major component of the extracellular
matrix (ECM) (3). MDa HA accumulates in demyelinating lesions,
where it promotes myelination failure by blocking maturation of
oligodendrocyte progenitor cells (OPCs) (4), which would otherwise mature into myelinating oligodendrocytes (5). HA fragments
(HAf) are generated when white matter injury (WMI) triggers
enhanced expression of hyaluronidases that depolymerize MDa
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HA (6, 7). In conditions such as sterile lung injury and wound
healing, ECM breakdown results in release of proinflammatory
HAf (8), which may function as an endogenous DAMP to regulate proinflammation via receptors that include CD44, TLR2, and
TLR4 (8). It is unclear, however, whether HAf may also function
as a DAMP in chronic WMI to disrupt myelination via a tolerance-like mechanism. OPCs express TLRs, but their stimulation
does not promote proinflammatory cytokine release (9). Although,
IκK/NF-κB signaling is the main proinflammatory pathway associated with TLR activation, it does not regulate developmental
myelination or remyelination (10). Despite evidence that HAf may
mediate adult myelination failure by utilizing a proinflammatory
signaling pathway (6), the proinflammatory actions of HAf have
been recently questioned and attributed to bacterial endotoxin
contamination (11). Consequently, the mechanistic roles for MDa
HA and/or HAf in regulating OPC differentiation in chronic WMI
remain poorly defined.
WMI in preterm human infants causes arrested maturation of late OPCs (preOLs) in chronic lesions that contributes
to cerebral palsy and chronic neurobehavioral disabilities (12).
We report here that neonatal WMI results in ECM breakdown
and a persistent reduction in MDa HA. To define potential roles
of HAf in chronic neonatal myelination failure, we generated
endotoxin-free HAf of narrowly restricted sizes. We identified
a specific bioactive HAf (bHAf) of approximately 200 kDa that
blocked OPC maturation cell autonomously. Sustained exposure of OPCs to bHAf led to desensitization of AKT, a potent
jci.org   Volume 128   Number 5   May 2018
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Figure 1. Neonatal rat H-I WM lesions deplete MDa HA. (A) Schematic diagram of the H-I strategy and postnatal ages for tissue analysis. (B and C) Representative images of the supracallosal WM of the corpus callosum (CC) and overlying cortex (Ctx) in control and H-I samples at P4 (B) and P14 (C) stained
for GFAP and HABP. Diffuse reduction in MDa HA persisted until P14 (C). (D) Recovery of total HA from WM lesions after H-I. Comparison of true controls
(Control), hypoxic controls (Hypoxia only), and H-I group (Lesion) versus contralateral hypoxic hemisphere (Contralateral). Only the lesion group had a
significant reduction in HA recovery. (E) Incubation of MDa HA with the lesion lysate generated HAf below ~650 kDa. Lesion-lysate activity was sensitive
to heat inactivation but insensitive to deferoxamine (50 μM). B and C: control n = 2; H-I n = 4 animals for each age group (P4 and P14). D: n = 6 (H-I),
n = 5 (control), and n = 4 (hypoxia) animals (P7). E: n = 4 separate experiments on 4 different animals at P4 after H-I at P3; one representative experiment
is shown. *P < 0.05 by ANOVA. Mean ± SD. Scale bars: 300 μm (B and C).

pro-myelination signal (13). This tolerance-like action of bHAf
was mediated through TLR4 but not via CD44 or TLR2. As
in TLR4-mediated IT, bHAf ’s influence on myelination was
reversible when MDa HA depolymerization was attenuated or
bHAf was removed. AKT desensitization was similarly reversible in vivo in neonatal WMI. Moreover, bHAf actions were
mediated via a noncanonical TRIF-dependent pathway, also
involved in IT, rather than the canonical MyD88 arm of TLR4
signaling. AKT desensitization resulted in maturation-dependent activation of the FoxO3 transcription factor (TF), which
selectively constrained preOL maturation in a bHAf-dependent
fashion. A role for activated FoxO3 in human myelination failure was supported by selective localization of nuclear FoxO3
to OPCs in human preterm WMI and multiple sclerosis (MS)
plaques. bHAf-mediated OPC maturation arrest appears to be
regulated at the FoxO3 and myelin basic protein (MBP) promot2026
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ers by interactions of FoxO3 with the chromatin-remodeling
factor Brg1 and the TF Olig2, which are involved in control of
OPC differentiation (14–16). Hence, central myelination failure is regulated by a noncanonical TLR4/AKT/FoxO3 signaling
pathway utilized by bHAf to induce a tolerance-like state that
selectively constrains OPC maturation and myelination.

Results

Neonatal hypoxic-ischemic WMI promotes MDa HA depolymerization. To investigate the status of MDa HA in chronic neonatal
WMI, we employed our preterm-equivalent rat hypoxia-ischemia
(H-I) model, which generates myelination failure and replicates
key features of human WMI (Figure 1A) (17). MDa HA turnover
in the ECM after H-I was visualized with a biotinylated HA-binding protein (HABP) and costained with glial fibrillary acidic protein (GFAP) as a marker of WMI. Unlike in age-matched unin-
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jured control white matter (WM), diffuse astrocyte activation was
observed within 24 hours after H-I in the corpus callosum at P4
(Figure 1B). HABP staining revealed uniform distribution of MDa
HA in control gray and white matter at P4 (Figure 1B and Supplemental Figure 1A; supplemental material available online with this
article; https://doi.org/10.1172/JCI94158DS1). However, MDa
HA staining was markedly reduced throughout early WMI (Figure
1B). In contrast to controls at P14, chronic WMI displayed extensive reactive astrogliosis and a persistent diffuse reduction in MDa
HA (Figure 1C).
To obtain a quantitative estimate of MDa HA depolymerization in neonatal WMI, we isolated HA from neonatal brain
tissue for analysis by size exclusion chromatography coupled to
multi-angle light scattering (SEC-MALS). Lesions showed a significant pronounced decrease in MDa HA content relative to true
controls (Figure 1D). There was no significant reduction in MDa
HA recovery from the contralateral hypoxic hemisphere or from
exposure to hypoxia alone (Figure 1D).
We next examined expression of enzymes that regulate HA
levels in neonatal WMI. We found no changes in expression of HA
synthases 1–3 (Supplemental Figure 1B), which generate different
HA sizes (8). De-polymerization of MDa HA by hyaluronidases can
generate large (300 kDa–1 MDa), intermediate (20–300 kDa), or
small (<20 kDa) HAf, which regulate distinct signaling pathways
(18). Previous reports implicated MDa HA depolymerization by
the hyaluronidase PH20 in regulation of re-myelination in adult
models of WMI (refs. 6, 7; but also see ref. 19). We did not detect
PH20 expression in neonatal rat brain (Supplemental Figure 1B).
No changes in Hyal2 expression occurred after H-I, but there was
a significant decrease in expression of Hyal1, which generates
HAf oligomers (18). In contrast, expression of Tmem2, a recently
described membrane-associated hyaluronidase (20), was significantly elevated after H-I.
We next determined whether neonatal WMI had an enzymatic
activity that could generate HAf. When protein lysates made from
H-I lesions were incubated with exogenous MDa HA, HAf were
generated in a broad range below approximately 650 kDa (Figure
1E). However, HAf were not generated from pre-boiled protein
lysates (Figure 1E). Since non-enzymatic MDa HA depolymerization may occur by oxidative attack, we coincubated WMI lysates
with deferoxamine, because neonatal WM is highly enriched in
iron, which may catalyze production of superoxide radicals that
nonspecifically generate HAf. Under these conditions, MDa HA
depolymerization was still observed (Figure 1E). Hence, we isolated
an endogenous activity in response to neonatal WMI whereby MDa
HA is cleaved into a range of smaller fragments.
A distinct sized HA ligand is bioactive and mediates OPC maturation arrest. To define a role for MDa HA depolymerization in
myelination failure, we first determined whether myelination
occurred in our in vitro slice culture model of chronic WMI. This
model reproduces key features of neonatal WMI including OPC
maturation arrest, which is enhanced by MDa HA (21). Since slice
cultures were prepared from P1 animals, myelin was not present.
However, between 14 and 21 days in culture, we visualized extensive staining for the juxtaparanodal myelin marker CASPR, consistent with formation of nodes of Ranvier (Figure 2A), and detected numerous neurofilament protein–labeled axons associated
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with MBP-labeled oligodendrocytes (Supplemental Figure 2A).
To confirm de novo progressive myelin generation, we undertook
ultrastructural studies that identified axons wrapped with multilamellar myelin sheaths (Figure 2B).
In contrast to vehicle-treated slices, which displayed robust
myelination of the corpus callosum, slices incubated with MDa
HA until 21 days in vitro (DIV21) displayed a pronounced reduction in myelinated axons (Figure 2C). Myelination failure was not
related to decreased OPC survival, since MDa HA treatment did
not enhance OPC degeneration or decrease OPC density (Supplemental Figure 2, B–D). Notably, myelination comparable to
that in vehicle-treated controls was promoted by coincubation of
slices with MDa HA and VCPAL, a potent hyaluronidase inhibitor
(22) (Figure 2C). We confirmed that the effect of VCPAL was cell
autonomous. Consistent with prior studies (4, 6, 19), incubation
of differentiating primary OPC cultures with MDa HA induced a
significant decrease in the percentage of mature MBP+ OLs, which
was significantly reversed by coincubation of primary OPCs with
MDa HA and VCPAL (Supplemental Figure 2E). Hence, the disruption of myelination by MDa HA appeared to be cell autonomous and mediated by MDa HA depolymerization induced by
hyaluronidase activity.
Since we had identified an endogenous activity in neonatal
WMI lysates that generated a range of smaller HAf (Figure 1E),
we performed an in vitro screen for a bioactive size range of HAf
that blocks OPC maturation. We first screened polydispersed fractions of HAf, which contained a continuum of HA sizes, to define
size ranges that blocked OPC differentiation. HAf sizes between
175 and 300 kDa attenuated OPC maturation, whereas small
(5–20 kDa) HAf ranges lacked activity (Figure 2D). To more narrowly define the size of bHAf, we prepared endotoxin-free monodisperse HAf (40, 106, 210, and 357 kDa) by SEC fractionation
of polydispersed fractions of HA (23) and screened them in slice
cultures. OPC maturation was not blocked by 40-, 106-, or 357kDa HAf (Figure 2E). In contrast, treatment with 210-kDa HAf
decreased OPC maturation (Figure 2E). We confirmed that bHAf
blocked maturation of primary OPC cultures in a cell-autonomous
manner (Figure 2F). Moreover, after sonication of MDa HA and
bHAf, these preparations failed to block OPC maturation (Supplemental Figure 2F). Notably, bHAf persistently blocked OPC maturation and myelination in slice cultures up to DIV21 (Figure 2C and
Supplemental Figure 2G).
We next determined whether the effect of bHAf on OPC
maturation was concentration dependent or altered by coincubation with HAf of different sizes. Concentrations of 100–200 nM
attenuated OPC maturation in slices, whereas lower or higher
concentrations lacked activity, which suggested a narrow critical
concentration range for biological activity (Figure 2G). To attempt
to out-compete and block bHAf activity, we cotreated slices with
100 nM bHAf and equimolar concentrations of inactive HAf (40,
106, or 357 kDa). Neither HAf sizes smaller nor those larger than
210 kDa disrupted bHAf activity, supporting the hypothesis that
bHAf selectively blocks OPC maturation (Figure 2H). Hence, our
findings indicate that attenuation of OPC maturation in the lesion
microenvironment is dependent on generation of an effective concentration of bHAf by hyaluronidase activity, and that bHAf with a
distinct size of about 200 kDa is required.
jci.org   Volume 128   Number 5   May 2018
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Figure 2. A distinct bHAf blocks OPC maturation. (A–C) Rat slices cultured
21 days display extensive myelination. (A) Nodes of Ranvier identified with
CASPR (red arrowheads). (B) Representative ultrastructural images of early
(left panel) and late (right panel) myelination and detail of multilamellar
myelin sheaths (insets). (C) Schematic of strategy to analyze chronic in
vitro myelination. prep, prepared from. Representative images of myelinated axons in callosal WM visualized with MBP and 200 kDa neurofilament
H (NFH) after treatment with DMSO (vehicle), MDa HA (50 nM) with or
without VCPAL (25 μM), or bHAf (100 nM). (D) 175–300 kDa HAf regulates
OPC maturation cell autonomously. Primary OPCs cultured 4 days under
pro-differentiation conditions stained for OPCs (PDGFRα, green), OLs
(MBP, red), and DAPI (blue). Cultures treated with PBS (vehicle), MDa HA
(50 nM), HAf 175–300 kDa (500 nM), or HAf 5–20 kDa (500 nM). Quantification of total OPCs and OLs. (E) MBP+ OLs in DIV8 slices cultured with
PBS (vehicle) or HAf of 40 (100 nM), 106 (100 nM), 210 (100 nM) or 357 kDa
(100 nM). (F) Primary OPCs differentiated 4 days with or without bHAf
(500 nM) visualized with cyclic nucleotide phosphodiesterase (CNP), MBP,
and DAPI (left). bHAF treatment decreased the percentage of OLs (right).
(G) Density of OLs in DIV8 slices cultured with varying bHAf concentrations. (H) OL quantification in DIV8 slices cultured with bHAf (100 nM) and
equimolar concentrations of HAf at 357 or 106 kDa or combined with 357kDa and 106-kDa HAf (100 nM). A, C, and E: n = 3 animals/condition from
separate litters; 3 slices/treatment condition/animal, 9 slices total. D and
F: n = 2 separate culture preparations. G and H: n = 1 animal per condition;
3 slices analyzed per treatment condition. *P < 0.05 by Student’s t test;
**P < 0.001 by ANOVA; mean ± SD. Scale bars: 12 μm, A; 600 nm, B (insets:
original magnification, ×33,000); 150 μm, C; 75 μm, D and F.

bHAf regulates AKT in a tolerance-like manner. HAf-mediated
downstream signaling has been linked to regulation of AKT and
MAPK signaling pathways (8). MAPK and AKT also have well-
documented roles in CNS myelination (24). Sustained constitutive
AKT phosphorylation is linked with enhanced myelination (13). We
first determined in slice cultures whether bHAf influences these
signaling pathways. bHAf induced AKT phosphorylation at 15 minutes. However, phosphorylation of both T308 and S473, the two residues associated with maximal AKT activation, was not sustained
and returned to baseline by 4 hours (Figure 3A). In contrast, MAPK
activation, as defined by ERK1/2 phosphorylation status, did not
change significantly, even after 4 hours of bHAf treatment (Figure
3A). AKT phosphorylation remained attenuated after a 24-hour
exposure to bHAf (Figure 3B) and even at 9 days (Figure 3C).
To determine whether bHAf selectively induced a refractory
state of AKT signaling, we incubated slices with brain-derived
neurotrophic factor (BDNF), which robustly stimulates AKT activation and protects against cerebral injury during neonatal H-I
(25, 26). In contrast to bHAf, BDNF sustained AKT activation
at 4 and 24 hours (Figure 3D). We next hypothesized that if persistent exposure to bHAf causes chronic desensitization of AKT
activation, then AKT should remain refractory to costimulation by
another potent AKT activator, such as BDNF. Slices were exposed
to bHAf or BDNF, followed by restimulation with the same factor
(Figure 3E). Slices remained refractory to AKT activation upon
restimulation with bHAf. However, restimulation with BDNF
induced AKT activation, indicating that initial BDNF treatment
does not induce a refractory state that renders subsequent insensitivity to BDNF. Notably, BDNF treatment was unable to induce
AKT activation in slices that were pretreated with bHAf. Hence,
continuous bHAf exposure promoted sustained desensitization of
AKT that could not be overcome by costimulation with BDNF.
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We next determined whether chronic hypoxic-ischemic neonatal WMI is also associated with persistent AKT desensitization
(Figure 3F). At 24 hours after H-I (P4), AKT phosphorylation at
S473 and T308 was reduced versus that of age-matched uninjured
controls. Attenuated AKT phosphorylation persisted at P7 and P10.
However, at P14 and P21, AKT phosphorylation was comparable to
that of controls. We thus hypothesized that if attenuation of AKT
phosphorylation was related to myelination delay, recovery of AKT
phosphorylation should coincide with the delayed onset of myelination. We quantified MBP staining as a surrogate marker of myelination at P10, P14, and P21 after H-I at P3 (Figure 3G). MBP staining
was markedly reduced at P10, consistent with a reduction in AKT
activation in chronic lesions. However, at P14 and P21, the levels of
MBP in the WM and cortex increased significantly, consistent with
a progressive partial increase in myelination. Moreover, in resolving WMI at P21, lesions did not display persistent digestion of MDa
HA, but rather had more normalized MDa HA staining (Supplemental Figure 3). Given that H-I–induced AKT inactivation was
reversible and coincided with MDa HA accumulation, we hypothesized that bHAf generation during WMI creates a permissive state
that negatively influences OPC maturation in a reversible fashion.
We first treated slices with MDa HA and then cultured them without MDa HA (Supplemental Figure 4, A and B), which resulted in
an MBP+ OL density comparable to that in controls. Hence, the
presence of bHAf in WM lesions is permissive to sustain a tolerance-like state of AKT desensitization, but upon its removal, OPCs
remain competent to differentiate.
bHAf signals via TLR4 but not TLR2 or CD44 to mediate OL
maturation arrest. Given that TLRs play prominent roles in regulating IT (2) and CD44 can regulate either TLR2 or TLR4 signaling
(8), we determined whether these receptors were involved in bHAf
signaling. We adapted our rat slice culture model to knockout mice
(Figure 4A). We confirmed that treatment of WT cultures with
either MDa HA or bHAf blocked OPC maturation (Figure 4B). We
next analyzed slices prepared from CD44–/– pups. MDa HA failed
to block OPC maturation, but bHAf significantly decreased the
density of MBP+ OLs (Figure 4C). Hence, bHAf action was not
mediated via CD44, but CD44 appeared to play a role in the recognition and size processing of MDa HA, as previously reported (27).
We next explored a potential role for TLR2 or TLR4 in bHAf
actions. As in CD44–/– mice, MDa HA failed to block OPC maturation but bHAf blocked OPC maturation in TLR2–/– mice (Figure 4D).
However, OPC maturation in TLR4–/– mice was insensitive to either
MDa HA or bHAf (Figure 4E). We next confirmed that bHAf signals
in a cell autonomous manner via TLR4 but not TLR2. The maturation of TLR2–/– primary OPCs was blocked by bHAf, but OPCs from
TLR4–/– pups fully differentiated in the presence of bHAf (Supplemental Figure 5). Hence, TLR4 was required for mediation of the
inhibitory effects of bHAf on OPC maturation. Given the previously
reported complex signaling crosstalk between TLR2 and TLR4 in
the brain (28), we determined whether this requirement for TLR4
might be lost with TLR2 deletion by analyzing slices from TLR2–/–
TLR4–/– mice. These animals were insensitive to either MDa HA or
bHAf treatment, which further supported that even with TLR2 deletion, TLR4 deletion still blocked the actions of bHAf (Figure 4F).
Collectively, these observations support that bHAf signals via TLR4
to block OPC maturation during chronic WMI.
jci.org   Volume 128   Number 5   May 2018
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Figure 3. bHAf regulates AKT in a tolerance-like manner. (A–C) bHAf
induces persistent AKT dephosphorylation in rat slices treated with bHAf
(100 nM). Representative blots and quantification after probing with
pAKT-S473, pAKT-T308, pERK1/2, AKT (total AKT), and actin antibodies.
Note the transient increase in AKT phosphorylation followed by persistent
reduction to control levels at 4 hours (A), 24 hours (B), and 5 or 9 days
(C). (D) BDNF (50 ng/ml) induces persistent AKT phosphorylation at 30
minutes, and 4 or 24 hours. (E) Experimental design to determine whether
BDNF can overcome bHAf-mediated AKT desensitization (left); and representative blots (right). (F) Chronic WMI leads to persistent AKT dephosphorylation that normalizes with delayed partial myelination. Representative blots and quantification from 3 rats that underwent H-I at P3 versus
control (C), comparing AKT phosphorylation in lesion hemisphere at P4, P7,
P10, P14, and P21. Actin was the loading control. (G) Progressive recovery of
myelination following WMI. Representative images depicting MBP staining at
P10, P14, and P21 (asterisks indicate H-I hemisphere). A–E: n = 3 independent
studies from 3 separate litters; 2 slices/condition. F: n = 3 animals (control)
and n = 6 animals (H-I). G: n = 9 animals/condition. *P < 0.05 by Student’s
t test; mean ± SEM. Scale bars: 600 μm, G.

bHAf signals via TRIF to regulate AKT. TLR4-mediated tolerance may be regulated at multiple levels via 2 distinct adaptors, MyD88 and TRIF (1, 2). We first determined which of these
adaptor proteins participates in bHAf signaling (Figure 5A). Both
MDa HA and bHAf caused a significant decrease in MBP+ OLs in
MyD88–/– slices (Figure 5B), which was similar to the response of
WT mice to bHAf (Figure 4B). Hence, the actions of neither MDa
HA nor bHAf appeared to be mediated via the canonical MyD88
signaling pathway. However, when we analyzed TRIF–/– pups,
neither bHAf nor MDa HA blocked OPC maturation (Figure 5C).
Hence, bHAf blocked OPC maturation through TLR4 via a noncanonical signaling pathway that utilized the TRIF adaptor protein.
We next determined whether TRIF is involved in bHAf-
mediated AKT activation. We treated slices from TRIF–/– or WT
pups with bHAf and determined AKT phosphorylation status.
Treatment with bHAf for 30 minutes did not cause significant
changes in AKT phosphorylation in TRIF–/– cultures (Figure 5D),
whereas AKT was phosphorylated in WT cultures (Supplemental
Figure 6A). We also analyzed AKT activation after 24 hours of bHAf
treatment in TRIF–/– (Figure 5E) and TLR4–/– (Figure 5F) slices and
similarly found no change in AKT phosphorylation status, which
further supported that bHAf signals via the TLR4/TRIF pathway.
We then determined whether negative regulators of TLR4 signaling act through a complex with TRIF. We examined the role of
TRAF6, an E3 ligase, which is a member of the TRIF signalosome
complex that plays a role in AKT ubiquitination and activation
(2, 29). Proteins with deubiquitinase activity, such as TNFAIP3/
A20 or β-arrestin2, can negatively regulate TRAF6 activity (29).
Since we found that bHAf led to a progressive increase in total
A20 protein levels in treated slices (Supplemental Figure 6B),
we determined whether bHAf-mediated AKT inactivation was
related to A20 recruitment into the TRIF-TRAF6 complex. We
isolated the TRAF6 complex by co-IP. We confirmed that the isolated complex contained the components of the signalosome by
probing it with TRIF and Pellino1/2 antibodies. Pellino proteins
are another member of the TRIF complex that can regulate TLR
signaling (30). Western blot analysis demonstrated that both TRIF
and Pellino1/2 were isolated as part of the TRAF6 co-IP, but we
did not detect A20 as part of the signaling complex (Supplemental
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Figure 6C). These observations suggest that although bHAf influences A20 induction, bHAf does not appear to play a role in A20
recruitment to the TRIF complex. We next investigated whether
bHAf influenced the recruitment of β-arrestin2, another negative
TRAF6 regulator, to the TRIF complex. bHAf did not change the
total β-arrestin2 level but led to transient recruitment of β-arrestin2 to the TRIF-TRAF6 complex (Figure 5F). Collectively, these
results support that β-arrestin2 is recruited to the TRIF-TRAF6
complex to attenuate AKT signaling in response to bHAf.
bHAf signaling regulates OL lineage maturation at the preOL
stage via FoxO3. To determine downstream targets of AKT activation, we first analyzed mTOR signaling, which plays a role in regulating OPC maturation and myelination (24). However, there were
no observed changes in mTOR phosphorylation status in response
to bHAf that would suggest a role in bHAf signaling (Supplemental Figure 6D). Prior observations suggested that AKT inactivation
results in GSK3β activation and that GSK3β inhibition enhances
OPC maturation (31). We thus hypothesized that if bHAf blocked
OPC maturation via GSK3β activation, treatment with a GSK3β
kinase inhibitor should promote OPC maturation. bHAf treatment
attenuated GSK3β Ser9 phosphorylation, which suggested activation of the kinase (Supplemental Figure 6E). We next attempted to
block the effect of bHAf with pharmacological agents that target
Ser9 phosphorylation of GSK3β to inhibit the kinase. However, the
GSK3β inhibitors 6BIO (Supplemental Figure 6F) and LiCl (data
not shown) failed to promote OPC maturation, which supported
that GSK3β is not part of the bHAf signaling pathway.
We next explored a function for FoxO TFs, known AKT targets, which maintain tissue homeostasis and are sensitive to cellular stress (32). Studies with FoxO3 –/– mice found that FoxO3
induces a program that prevents premature differentiation of oligodendrocytes by repressing myelination genes (32). Given that
AKT phosphorylation was attenuated in chronic WMI until P10,
we hypothesized that if FoxO3 contributed to myelination delay,
FoxO3-labeled OPCs should be enriched in WM lesions arising
from neonatal rat H-I. We determined whether FoxO3 displayed
enhanced nuclear localization to PDGFRα-labeled OPCs in WMI
at P4–P10. Little FoxO3 staining was detected in control WM at
P7 (Figure 6A). However, robust FoxO3 staining localized to WM
lesions but did not colocalize with PDGFRα-labeled OPCs (Figure
6A). In chronic human neonatal WMI (17) and MS (33), myelination failure arises when OL lineage progression is blocked at the
late OPC (preOL) stage. Since we previously found that preOLs
also undergo arrested differentiation in chronic rodent WMI,
we determined whether FoxO3 localized to preOLs visualized
with the anti-O4 antibody. In controls at P7, a low level of cytoplasmic FoxO3 staining was detected that did not colocalize with
O4-labeled cells (Figure 6B). However, many O4-labeled cells
displayed robust FoxO3 nuclear label in WM lesions (Figure 6B).
Hence, maturation arrest of preOLs in chronic WMI coincided
with stage-dependent expression of FoxO3 in preOLs.
FoxO3 expression was similarly increased in slice cultures
treated with MDa HA for 21 days (Figure 6C) or bHAf for 24 hours
(Figure 6D and Supplemental Figure 7A). When we costained
slices with FoxO3 and the OL lineage marker and TF Olig2, few
FoxO3+Olig2+ colabeled cells were visualized in untreated slices,
but both MDa HA (Figure 6C) and bHAf (Figure 6D) increased the
jci.org   Volume 128   Number 5   May 2018
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Figure 4. bHAf signals via TLR4 but not TLR2 or CD44 to mediate OPC maturation arrest. (A) Strategy to analyze roles of CD44, TLR2, and TLR4 in
myelination failure. Quantification of MBP+ OL density in corpus callosum from murine forebrain slices treated with PBS (vehicle), MDa HA (2,000 kDa;
50 nM), or bHAf (210 kDa; 100 nM). (B) Treatment of slices from WT animals is compared against slices from mice with the following backgrounds: (C)
CD44–/–, (D) TLR2–/–, (E) TLR4–/–, and (F) TLR2–/– TLR4–/–. B–F: n = 3 animals (P3/P4 mouse pups) per condition for each genotype from separate litters;
3 slices analyzed/treatment condition/animal, 9 slices total. **P < 0.001 by ANOVA; mean ± SD.

number of Olig2+ cells that colocalized with FoxO3. As previously
described (32), we also observed some FoxO3 staining that did not
localize to OL lineage cells (Figure 6C and Supplemental Figure
7A), which suggested that variable expression of FoxO3 may occur
in different cell types in chronic WMI. Hence, bHAf regulates the
expression and cellular distribution of FoxO3 in OL lineage cells
during chronic WMI.
Activation of AKT inactivates and restrains FoxO3 in the cytosol (34). To test whether bHAf-mediated desensitization of AKT is
instructive in regulating FoxO3 activity in OPCs, we overexpressed
a mutant construct of FoxO3 (FoxO3TM) that lacks AKT phosphorylation sites and causes preferential nuclear localization (34). Primary OPCs were cotransfected with monomeric red fluorescent
protein (mRFP; to label transfected cells) and either WT FoxO3
(FoxO3WT) or mutant (FoxO3TM) plasmids and induced to differentiate with or without bHAf (Figure 6E). Treatment with bHAf
led to an approximately 50% decrease in MBP+ cells compared
with untreated controls. Remarkably, the maturation of OPCs that
were transfected with FoxO3TM but not treated with bHAf did not
differ significantly from that of untreated control cells. Notably,
treatment of FoxO3TM-transfected cells with bHAf had an additive
effect, significantly decreasing OL maturation when compared with
bHAf-treated control cells, which indicated that nuclear localization
of FoxO3 is not sufficient to block OPC maturation and bHAf stimulation is instructive and required. Importantly, when OPCs were
transfected with WT FoxO3, there was no significant amplification
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of bHAf treatment when compared with controls treated with bHAf
(Figure 6E). Hence, bHAf is required for downstream activation of
FoxO3, since transfection with FoxO3TM alone only mildly blocked
OPC maturation and required additional stimulation by bHAf to
promote significant OPC maturation arrest.
FoxO3 transcriptional regulation by bHAf involves Olig2 and the
chromatin-remodeling factor Brg1. Since our results support that
bHAf regulates FoxO3 expression, we examined bHAf-dependent
interactions between FoxO3 and other transcriptional regulators
of OPC differentiation. Olig2 can recruit Brg1, the ATPase subunit
of switch/sucrose non-fermentable (SWI/SNF) chromatin-remodeling protein complexes, to gene enhancers that drive OL differentiation (15). Furthermore, we recently demonstrated that Brg1
regulates OPC specification and OL maturation by controlling
expression of genes involved in early OL versus neuronal differentiation (16). In Caenorhabditis elegans, a homolog of FoxO3, FOXO
interacts with the SWI/SNF complex to regulate life span (35). We
therefore tested the possibility that FoxO3, like other genes that
influence OL differentiation, is regulated by SWI/SNF chromatin-remodeling factors recruited by Olig2 and that FoxO3 interacts with myelin gene promoters regulated by Olig2 and SWI/SNF
complexes. We were unable to demonstrate any protein-protein
interactions between Brg1 and FoxO3 by co-IP (data not shown).
However, when we performed ChIP assays, we found that under
conditions that promote OPC proliferation or differentiation in
primary culture, Brg1 and Olig2 were both bound to the same
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Figure 5. bHAf signals via TRIF to regulate AKT. (A) Strategy to define roles for MyD88 and TRIF in myelination failure. (B) OPC maturation was blocked in
MyD88–/– murine slices treated with MDa HA (50 nM) or bHAf (100 nM). (C) TRIF–/– slices treated with MDa or bHAf did not differ from those treated with
vehicle (PBS). (D and E) bHAf-induced AKT phosphorylation (pAKT-S473) is TRIF and TLR4 dependent. Representative blots and quantification from studies with TRIF–/– (D) or TLR4–/– (E) animals. (F) β-Arrestin2 (Arrb2) is rapidly recruited to the TRIF-TRAF6 complex following bHAf treatment. Lysates were
prepared from rat slices treated with or without bHAf (100 nM) at the indicated times and analyzed by IP using TRAF6 antibody. Representative blots were
probed with TRIF, TRAF6, and β-arrestin2 antibodies: IP (upper panel); total cell lysate (lower panel). B and C: n = 3–4 mice (P3/P4) per condition for each
genotype from separate litters; 3 slices/animal/treatment condition; 9–12 slices total. D and E: n = 2 mice (P3/P4) per condition for each genotype from
separate litters; 2 slices/animal/treatment condition. F: n = 2 experiments from 2 separate litters; 2 slices/condition. *P < 0.05 by ANOVA; **P < 0.001 by
ANOVA; mean ± SD (B and C) and mean ± SEM (D and E).

region of the FoxO3 promoter (Figure 6F). This interaction was
disrupted by treatment of OPCs with bHAf, which displaced Brg1
from the FoxO3 promoter.
Since the transcription of several myelin genes, including
MBP, were inhibited in OPCs treated with bHAf (Supplemental
Figure 7B), we hypothesized that FoxO3 might interact with the
MBP promoter to influence Olig2-Brg1–dependent MBP transcription. To begin to define the mechanism by which FoxO3 regulates
MBP and other myelin genes, we analyzed interactions among
Brg1, Olig2, and FoxO3 at the MBP promoter in OPCs. Under conditions that promote OPC proliferation, Brg1, Olig2, and FoxO3
were found to interact at the same regions of the MBP promoter,
but under pro-differentiation conditions FoxO3 was displaced
from the promoter (Figure 6G), consistent with the notion that
FoxO3 acts as a transcriptional repressor of MBP. However, when
pro-differentiation conditions were combined with bHAf treatment, Brg1 and Olig2 were also displaced together with FoxO3
from the MBP promoter (Figure 6, G and H). These results are
consistent with the hypothesis that FoxO3 represses myelin gene
expression at least in part by disrupting transcriptional activation

mediated by SWI/SNF complexes recruited to myelin promoters
by Olig2. These data further indicate that bHAf inhibits OPC maturation through a mechanism whereby FoxO3, Brg1, and Olig2 are
all dissociated from myelin gene promoters under conditions that
would otherwise favor OL differentiation.
FoxO3 expression is markedly increased in oligodendroglia in
chronic human WMI from preterm neonates and adults with MS. Since
our findings supported that nuclear FoxO3 localization is related
to myelination failure, we determined whether this signaling paradigm was conserved in chronic human WMI and if FoxO3 could
be used as a surrogate readout of tolerance-like dysregulation of
human OPC maturation. We first determined the patterns of FoxO3
expression in autopsy samples from 4 individuals with preterm
WMI where we previously demonstrated that arrested preOL maturation occurred in lesions enriched in reactive astrocytes and HA
(17). Numerous FoxO3-labeled cells defined the boundaries of diffuse WMI (Figure 7A, left panel), but FoxO3 staining was markedly
reduced in normal-appearing WM adjacent to the lesion (Figure 7A,
middle). In WM lesions (Figure 7A, right), diffuse FoxO3 staining
localized to numerous reactive astrocytes and nuclei.
jci.org   Volume 128   Number 5   May 2018
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Figure 6. bHAf signaling regulates OL lineage maturation at the preOL stage
via FoxO3. (A) Elevated FoxO3 expression in chronic WMI in corpus callosum 4
days after H-I. Insets: The number of FoxO3-labeled cells (green; open arrowheads) is increased in WMI, but they do not colocalize with PDGFRα-labeled
progenitors (red; filled arrowheads). (B) Nuclear localization of FoxO3 was
detected 4 days after H-I in O4-labeled cells in WMI but not controls. (C) Rat
slices treated 21 days with or without MDa HA (50 nM). MDa HA significantly
increased Olig2+FoxO3+ cells in corpus callosum (white arrowheads) versus PBS
controls. (D) Total Olig2+ and Olig2+FoxO3+ cells in the entire corpus callosum
from rat slices treated 24 hours with or without bHAf (100 nM). (E) Primary
mouse OPC cultures were cotransfected with the indicated constructs and
mRFP (red) and induced to differentiate for 4 days with or without bHAf (500
nM). OPCs expressing FoxO3TM displayed a significant decrease in the total
percentage of MBP-labeled OLs versus cells expressing FoxO3WT or control
plasmids. (F and G) Molecular interactions among FoxO3, Brg1, and Olig2 in
proliferating and differentiating OPCs and in response to bHAf (500 nM). ChIP
assay defining Brg1 and Olig2 interactions with the FoxO3 promoter (F). ChIP
assay defining FoxO3, Brg1, and Olig2 interactions with the MBP promoter (G).
(H) Working model depicts that FoxO3 associates with SWI/SNF and Brg1 at
the MBP promoter in proliferating OPCs but dissociates from the promoter
(blue arrow) when pro-myelination signals induce OPC differentiation, consistent with FoxO3 repression of MBP transcription. When bHAf inactivates
AKT and drives FoxO3 nuclear localization, SWI/SNF and Olig2 dissociate
from the MBP promoter, blocking its transcription. A and B: n = 2 control and
n = 3 H-I animals. C: n = 2 animals/condition from 2 litters; 6 slices total, 3
slices/condition/animal. D: n = 3 animals/condition; 3 litters; 9 slices total, 3
slices analyzed/condition/animal. E: n = 3 separate experiments and culture
preparations. F and G: n = 2 separate experiments from separate culture
preparations. *P < 0.05 by Student’s t test (E); **P < 0.001 by Student’s t
test (D); mean SEM. Scale bars: 300 μm, A (insets: original magnification,
×40); 10 μm, B; 40 μm, C. Original magnification, ×20 (E).

We analyzed FoxO3 expression in autopsy samples from 4 individuals with chronic MS plaques. To assess FoxO3 expression in
uninjured WM relative to demyelinated or partially remyelinated
MS plaques, we costained for the myelin marker MBP. MBP staining defined both the chronic active (Figure 7B, left panel) and active
remodeling (Figure 7C, left) MS plaques. In chronic active plaques,
FoxO3-labeled nuclei were diffusely localized at the plaque borders,
where sparse myelination and myelin debris were present (Figure 7B,
middle), as well as in the demyelinated core (Figure 7B, right). FoxO3
expression in reactive astrocytes demarcated the plaque borders and
was also detected in the lesion core (Figure 7B, right, and Supplemental Figure 8A). Within active remodeling plaques, FoxO3 localized to
numerous nuclei interspersed near sparse myelination (Figure 7C,
middle). However, in heavily myelinated WM distal to the plaque,
few FoxO3-labeled nuclei were detected (Figure 7C, right).
Since FoxO3 localized to the nuclei of OPCs that displayed
arrested maturation in rat H-I lesions (36) (Figure 6B), we next
determined whether FoxO3-labeled nuclei in human lesions also
localized to the OL lineage. To visualize OL lineage cells in paraffin-embedded neonatal tissue, we employed the pan-OL lineage
marker Olig2, which robustly identified lesions where an expanded pool of OL progenitors had arrested maturation (17). Numerous
Olig2+ nuclei colocalized with FoxO3 in neonatal WM lesions (Figure 7D and Supplemental Figure 8B). Similarly, in chronic active
MS plaques, numerous Olig2+ nuclei colocalized with FoxO3
(Figure 7D and Supplemental Figure 8C). Hence, oligodendroglial cells that expressed nuclear FoxO3 were present both in chronic preterm human WMI and MS plaques, and the persistence of
these cells may contribute to myelination disturbances after WMI.

Discussion

IT induction in the innate immune system following repeated
exposure to DAMPs is an evolutionarily conserved mechanism
to prevent excessive inflammation in response to infection or tissue injury (2). During early inflammation, depolymerization of
MDa HA attenuates macrophage/monocyte activation and blocks
inflammation in several contexts (1). Neonatal WMI also triggers
early and persistent ECM breakdown in chronic lesions where
delayed myelination occurs. We succeeded in isolating an endogenous activity in neonatal WMI lysates that cleaves exogenously
added MDa HA into a range of fragment sizes. We defined a role
for specific HAf that induce a tolerance-like state that attenuates AKT activation and promotes myelination failure. Disrupted
OPC maturation was selectively mediated via an approximately
200-kDa bHAf and was reversed when MDa HA depolymerization was blocked by a hyaluronidase inhibitor. bHAf signaled via
a noncanonical TLR4/TRIF pathway to dysregulate AKT/FoxO3
signaling. bHAf downregulated myelin gene expression through
a mechanism that includes dissociation of a SWI/SNF chromatin remodeling factor and Olig2 from myelin gene promoters.
Hence, our findings support the action of an IT-like mechanism in
response to WMI whereby chronic desensitization of AKT attenuates pro-myelination signals, which promotes an OPC niche at the
expense of myelination (Figure 6H).
During mammalian embryonic CNS development, hyaluronidase expression coincides with low MDa HA accumulation, but
postnatally MDa HA accumulates whereas hyaluronidase expression is undetectable (18). WMI was accompanied by a pronounced
reduction in MDa HA. Decreased MDa HA may be mediated by
HA synthases that are induced to generate only small HAf (37).
Our analysis of neonatal H-I lesions supports that depletion of
MDa HA was related to enhanced hyaluronidase expression. From
in vitro models of adult WMI, hyaluronidase PH20 was proposed
to play a role in delaying remyelination mediated by MDa HA (6,
7). A recent report has questioned this role of PH20 (19). We did
not detect PH20 expression in normal or injured neonatal brain,
which may suggest that PH20 expression is maturation dependent or transient. In response to neonatal WMI, we observed
decreased expression of Hyal1, a hyaluronidase involved in secretion of small-sized HAf from endocytosed HA (18) and increased
Tmem2, a recently identified hyaluronidase that generates intermediate-sized HAf (20). This prompted us to explore the hypothesis that intermediate-sized HAf block OPC maturation. We
screened highly pure endotoxin-free HAf sizes and identified a
bHAf of approximately 200 kDa.
Emerging studies have identified unique conformational
properties of the approximately 200-kDa bHAf that may account
for its selective dysregulation of myelination after WMI (38). As
a polymer in solution, MDa HA largely exists as a stiff random
coil. However, multiple studies found that as HA size decreases
it transitions from a random coil to a rod-like conformation (38).
This size-dependent conformational transition occurs in the range
of 100–300 kDa, and HAf of more than 300 kDa may essentially
have the same conformation as MDa HA (38). That the effects of
bHAf we observed were not attenuated in competition studies with
other HAf sizes further suggests unique biological properties at this
size range. The conformation of bHAf may also induce binding of
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Figure 7. FoxO3 expression is markedly
increased in oligodendroglia in chronic
human WMI from preterm neonates and
adults with MS. Robust FoxO3 expression
localized differentially to the cytoplasm of
astrocytes and nuclei of Olig2+ oligodendroglia in chronic human WMI. (A)
Left: Low-power image of preterm WMI
(Supplemental Table 1A; case 3). Diffuse
FoxO3 staining defined boundaries of this
large lesion between the cortical mantle
(arrowheads) and the lateral ventricle (not
shown). Middle: Rare FoxO3-labeled cells
(red arrowheads) in normal-appearing WM
adjacent to the lesion. Right: FoxO3 localized to numerous reactive astrocytes (red
arrowheads) and nuclei (black arrowheads)
in the lesion. (B) FoxO3 expression in a
chronic active MS plaque (Supplemental
Table 1B; case 1). Left: Low-power image of
a chronic active plaque stained for FoxO3
and MBP with markedly reduced MBP
staining in the core versus the peri-plaque.
Middle: Detail of the plaque edge shows
scattered MBP-labeled myelin debris
(brown) and numerous FoxO3-labeled
nuclei (black arrowheads). Right: Within
the plaque core, no myelination was visualized, but many FoxO3-labeled nuclei (black
arrowheads) were interspersed among
reactive astrocytes (red arrowheads). (C)
FoxO3 expression in an active remodeling
MS plaque (Supplemental Table 1B; case
1). Left: Low-power image of the plaque
stained for FoxO3 and MBP with scattered
islands of remyelination within the lesion.
Middle: Numerous FoxO3-labeled nuclei
(black arrowheads) localized among sparsely myelinated axons (brown). Right: A heavily myelinated peri-plaque region with rare
FoxO3-labeled nuclei (black arrowheads).
(D) FoxO3-labeled nuclei in a preterm WM
lesion (Supplemental Table 1A; case 1) and
MS plaques (Supplemental Table 1B; case 3)
colocalized with the pan OL lineage marker
Olig2. Colocalization of Olig2 fluorescence
and FoxO3 colorimetric labeling is indicated
in the merge in red. Scale bars: 200 μm, A,
left; 20 μm, A, middle and right; 300 μm, B,
left; 20 μm, B and C, middle and right; 300
μm, C, left; 30 μm, D.

a particular hyaladherin to form a complex that is recruited by a
cell-surface or intracellular protein to form a unique signaling complex (38). For example, cell surface CD44 has higher binding affinity for HA in complex with the TSG-6 link module compared with
HA alone (39). The formation of such complexes with HAf may
explain why it has been technically challenging in multiple tissues
to detect endogenous bHAf in vivo. For example, recent studies
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with human breast milk found it to be highly enriched in HA sizes
from 100 to 1,500 kDa (40), which suggested a role for breast milk
in regulation of gut innate immune responses (41). Human milk
and a 35-kDa HAf similarly regulated gut immune responses, but
biochemical analysis did not detect enrichment of 35-kDa HAf in
human milk. In studies of bleomycin-induced murine lung fibrosis,
an HAf of 540 kDa was initially identified (42). Although an in vitro
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screen of purified HAf later identified a proinflammatory role for a
135-kDa HAf (43), this size was not enriched in murine fibrotic lung
tissue (42). Similarly, our in vivo biochemical analysis of H-I lesions
found an overall decrease in total MDa HA, but no enrichment of
the approximately 200-kDa bHAf.
Studies of noninfectious lung injury, skin lesions, wound healing,
and activation of immune dendritic cells have indicated various roles
for CD44, TLR2, and TLR4 in mediating HAf actions (8). We identified roles for CD44, TLR2, and TLR4 in regulation of OPC maturation after WMI. When either CD44 or TLR2 was deleted, bHAf but
not MDa HA retained activity to block OPC maturation.
However, TLR4–/– mice were insensitive to both bHAf and
MDa HA. Hence, contributions from CD44 and TLR2 appeared to
be required for MDa HA to block OPC maturation, whereas bHAf
actions specifically required an interaction with TLR4. Notably,
binding of larger-sized HA appears to be stabilized by multivalent
interactions with CD44, whereas smaller HAf has distinct binding
properties (44). Polydispersed HA of larger sizes in human milk
also requires both CD44 and TLR4 to mediate their biological
effects, whereas 35-kDa HAf works independently of CD44 (41).
Our findings similarly support a primary role for bHAf in mediating
OPC maturation arrest via TLR4 independent of CD44 and TLR2.
Thus, targeting CD44 and/or TLR2 to prevent MDa HA de-polymerization or TLR4 to prevent bHAf signaling may be an attractive
strategy to promote regeneration and repair of neonatal WMI.
In the context of neonatal WMI, TLR4 regulated AKT not but
MAPK in a TRIF-dependent manner. Similarly, a prior study of
normal myelination or remyelination did not support a role for the
IKK/NF-κB pathway downstream of TLRs (10). Persistent bHAf
treatment led to desensitization of AKT, which was not rescued by
BDNF. BDNF potently induces AKT activation via the TrkB receptor. Thus, bHAf-mediated desensitization of AKT signaling appears
to share characteristics with IT induced by persistent activation of
TLRs by endotoxins, which recruits negative regulators to dampen
multiple downstream signaling effectors (1, 2, 29). We found that
β-arrestin2, a known negative regulator of TLR signaling (29), was
rapidly recruited to the TRIF-TRAF6 complex, upstream of AKT
desensitization induced by bHAf. Attenuation of AKT activation
persisted for at least 9 days in vitro, which suggests involvement of
other signaling regulators in this pathway. Furthermore, the onset
of delayed myelination after neonatal H-I followed a similar time
course. That myelination was stimulated in neonatal WMI as AKT
phosphorylation normalized suggests that myelination failure may
be reversible when bHAf levels decline in chronic lesions. In fact,
even after prolonged exposure to MDa HA in primary (4) or slice
cultures, arrested OPC maturation was reversible when MDa HA
was removed. Since our findings suggest that attenuation of AKT
activation is reversibly dependent on ECM remodeling, it may be
feasible to design therapeutic strategies to promote myelination
by specifically targeting the signaling proteins that are involved in
mediating the tolerance-like state induced by bHAf.
Attenuation of AKT activity results in activation of GSK3β
kinase and FoxO TFs (34). Our results do not support a role for
GSK3β kinase in bHAf-mediated myelination failure and agree
with previous studies, using knockin mice, that found that regulation of GSK3β Ser9 phosphorylation appears to have no physiological actions in the nervous system (45). AKT is activated by inhibi-
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tors of GSK3β Ser9 phosphorylation (e.g., LiCl, 6BIO) (46), which
may account for observations that these inhibitors promoted OPC
maturation (31).
Several findings supported that bHAf regulates FoxO3 to block
preOL maturation. bHAf increased FoxO3+Olig2+ cells in chronic
in vitro slices. Moreover, forced expression of FoxO3TM, which
preferentially resides in the nucleus, did not block OPC maturation without bHAf treatment, which supports that initiation of
bHAf signaling is a requirement for FoxO3 activity. Olig2 and Brg1
both bind to the FoxO3 promoter in a bHAf-dependent manner,
which suggests that FoxO3, like other factors that regulate OL
differentiation, is transcriptionally regulated by Olig2-recruited
SWI/SNF complexes and that bHAf controls FoxO3 transcription
by disrupting these interactions. Furthermore, FoxO3 interacts
with the MBP promoter in a region where Olig2 and Brg1 also
interact, and FoxO3 is dissociated from the MBP promoter as
OPCs differentiate. This suggests a mechanism by which FoxO3
acts to restrict OPC differentiation. Given that FoxO3 co-associates with Brg1 and Olig2 at the MBP promoter, it is possible that
FoxO3 blocks MBP transcription by interfering with the activities
of SWI/SNF complexes recruited to the promoter by Olig2. Interestingly, our data also show that under differentiation conditions
in the presence of bHAf, Brg1 and Olig2 are also dissociated from
the MBP promoter, which suggests that bHAf signaling leads to
dissociation of Olig2 from the promoter to block transcription.
The actions of nuclear FoxO3 in promoting OPC maturation
arrest appeared to be exerted in a maturation-dependent fashion
in vivo through selective nuclear localization to preOLs. In contrast, in chronic preterm WMI and MS plaques, cytoplasmic FoxO3
demarcated lesion boundaries by robustly localizing to reactive
astrocytes, as a potential marker of chronic ECM remodeling.
Although our results support that bHAf blocks preOL maturation via FoxO3, the role of other FoxO isoforms in neonatal WMI
is unclear. FoxO TFs appear to exert redundant effects to coordinately regulate diverse pathways to modulate neural stem cell or
progenitor cell homeostasis (32, 47). In a mouse model of chronic
neonatal hypoxia, FoxO1 was shown to promote OPC proliferation (48). It is thus interesting to note that TGF-β signaling regulates the timing of myelination by mediating interactions between
FoxO1 and Sp1, another TF that regulates OPC maturation (49).
Wnt signaling is another negative regulator of OPC maturation
during WMI that also downregulates Sp1-mediated transcription
(50). However, TGF-β signaling does not regulate subcellular distribution of FoxO3 or AKT activation (51), whereas bHAf-mediated
AKT desensitization drives FoxO3 activation. Given that activation
of FoxO3 initiates a positive feedback loop that promotes transcription of FoxO1 and FoxO4 (52), it will be interesting to determine
the epigenetic relationships between different FoxO TFs and Sp1
during chronic WMI and their influence on myelination failure.
Definition of the pathogenetic mechanisms that regulate the
generation and actions of bHAf may suggest repair strategies in
several neonatal and adult human disorders where WMI results in
chronic myelination failure. Persistent signaling by bHAf via the
TLR/TRIF pathway results in chronic desensitization of AKT, and
FoxO3 activation sustains arrested preOL maturation and myelination failure. Strategies to reverse this tolerance-like state appear
to represent a novel approach to promote myelin regeneration.
jci.org   Volume 128   Number 5   May 2018
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Methods

Pharmacological reagents. Endotoxin-free, pharmaceutical-grade
high-molecular-weight HA (MDa HA; >1.8 MDa; <0.1 EU/mg) and
polydispersed HAf (5–20 kDa, <0.01 EU/mg; and 175–300 kDa, <0.05
EU/mg) were from Lifecore Biomedical. HA of defined narrow-size
ranges (monodispersed) were prepared from Lifecore polydispersed
HA by SEC fractionation (23). Groups of 3 fractions with similar masses, assessed by SEC-MALS, were pooled from multiple column runs
and concentrated, and final HA weight-average molar mass (Mw),
96% size distribution, concentration, and endotoxin levels were determined: 40-kDa HAf (<0.004 EU/mg), 106-kDa HAf (<0.002 EU/mg),
210-kDa HAf (<0.002 EU/mg), and 357-kDa HAf (<0.002 EU/mg).
All HA stocks were made in endotoxin-free PBS. 3-[1-[3-(dimethylamino)propyl]-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole2,5-dione (Go6983) and (2′Z,3′E)-6-bromoindirubin-3′-oxime (6BIO)
were from TOCRIS Bioscience. LiCl was from MilliporeSigma. BDNF
was from PeproTech.
Animals. The following strains were from the Jackson Laboratory: CD44-KO (B6.129(Cg)-CD44tm1hbg/J; stock no. 005085); TLR2-KO
(B6.129-Tlr2tm1Kir/J; stock no: 004650); TLR4-KO (B6.B10ScN-Tlr4lps-del/
JthJ; stock no: 007227); MyD88-KO (B6.129P2(SJL)-Myd88tm1.1Defr/J; stock
no: 009088); TRIF-KO (C57BL/6J-Ticam1Lps2/J; stock no: 005037). WT
C57BL/6 mice from the Jackson Laboratory served as strain-matched
controls. TLR2–/–TLR4–/– mice were provided by Salman Qureshi
(McGill University, Montreal, Quebec, Canada) (53). E17 timed-pregnant Sprague-Dawley (SD) rats were from Charles River.
Neonatal H-I. Unilateral cerebral H-I was studied in P3 rats as
described previously (36). Untreated true controls and H-I animals
survived until P4, P7, P10, P14, or P21. Only brains with grossly visible
cerebral pallor or swelling were analyzed by IHC (36) or were rapidly
dissected, snap frozen in liquid nitrogen, and stored at –80oC for RNA,
protein, and HA analyses. A minimum of 5 brains were analyzed at
each time point. Up to 20 animals from 2 separate litters were combined without identifiers for H-I. Studies were repeated at least once
for a minimum of 4 litters entered into each analysis.
In vitro hyaluronidase assay and SEC-MALS. For the in vitro hyaluronidase assay, protein lysates were prepared from WM lesions from
P4 rats that underwent H-I at P3. Lysates were prepared in ice-cold 1×
RIPA buffer containing protease inhibitor cocktail (MilliporeSigma).
Lysates (40 μg) were incubated with MDa HA (8 μg) in buffer containing 1% TX-100, 150 mM NaCl, 100 mM formic acid, pH 4.0, at 37°C
for 4 hours. Some protein lysates were heat inactivated by boiling for
30 minutes or treated with deferoxamine (10 μM; MilliporeSigma)
before incubation with MDa HA. Samples were briefly centrifuged,
and 10 μl of reaction solution was loaded onto 0.5% agarose gels for
electrophoresis for 3 hours at 20 V at 4°C. Gels were stained with
Stains-all (Polysciences Inc.) and imaged using the Odyssey Infrared
system (Li-COR Biosciences).
HA concentration and Mw in brain tissues was determined by SECMALS using 2 or 3 PL Aquagel-OH 60, 40, and 20 (Polymer Labs) size
exclusion columns in series (7). MALLS analyses of the SEC column
eluate was performed in-line using a Dawn DSP Laser Photometer in
series with an Optilab DSP Interferometric Refractometer (both from
Wyatt Technologies). Data were analyzed using ASTRA version 4.73,
with dn/dc values of 0.153 ml/g, and first-order Berry fits.
Forebrain slice culture and primary OPC culture. Whole forebrain
coronal slices (300 μm) were prepared from P0/P1 rats or P3/P4 mice
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for organotypic cultures as described previously (21). Mouse slices
were cultured without penicillin and streptomycin. Half-media changes were done every other day up to DIV7–DIV8 or DIV21 (rat) or DIV3–
DIV4 (mouse).
Primary OPC cultures were derived from oligospheres (7) or by
immunopanning (54). For OPC differentiation experiments, OPCs
were plated at 5 × 104 cells per coverslip and differentiated in DMEM/
F12 medium containing 0.1% BSA plus triiodothyronine (T3; 30 nM;
MilliporeSigma) and N-acetyl-l-cysteine (NAC; MilliporeSigma) for
4 days with or without HAf (500 nM) of indicated sizes. Cells were
fixed in ice-cold 4% paraformaldehyde for 1 hour at room temperature prior to IHC.
Plasmids and cell transfection. HA-FoxO3WT and HA-FoxO3TM
plasmids from Addgene were described previously (34). To verify
whether FoxO3 influences bHAf signaling, we cotransfected oligosphere-derived OPC cultures (5 × 104 cells) on glass coverslips with
mRFP using Lipofectamine 2000 (Invitrogen). The day after transfection, differentiation was induced in the presence or absence of
bHAf (500 nM) for 4 days. Cells were fixed at room temperature for
15 minutes in 4% paraformaldehyde and 4% sucrose in PBS, permeabilized with 0.1% TX-100 in PBS for 10 minutes, and visualized with
rat anti-MBP antibody (1:500; MAB386; EMD Millipore). Primary
antibody was visualized with anti-rat–Alexa 463 (1:500; Invitrogen).
Fluorescence images were acquired at 20× with a cooled CCD camera
(Hamamatsu Photonics) attached to a Zeiss Imager.M2 upright microscope. 2,000–3,000 cells were counted per coverslip; 4 coverslips
were analyzed per condition from 2–3 independent experiments. Cell
counts employed the cell counting plugin in FIJI software.
Real-time PCR analysis. P3 animals were analyzed at 24 hours
after H-I. Control and WM lesion tissue were microdissected and
resuspended in TRIzol (Life Technologies) to extract total RNA. 250
ng RNA was used to make cDNA using the TaqMan Reverse Transcription Kit (Applied Biosystems). cDNA was diluted 1:1 before realtime PCR (qPCR) experiments (TaqMan Gene Expressions Master
Mix, Applied Biosystems). All qPCR probes were FAM-MGB (Thermo
Fisher Scientific): Tmem2 (Rn01498397-m1), PH20 (Rn01500727-m1;
Rn01500728-m1; Rn00588656-m1), Hyal-1 (Rn02133715-S1), Hyal-2
(Rn01521340-g1), Has1 (Rn00597231-m1), Has2 (Rn00565774-m1), Has3
(Rn00597204-m1), MBP (Rn01399619-m1), Plp (Rn01410490-m1),
and Mog (Rn
00575354-m1). 18S RNA (Rn03928990-g1) was the
endogenous control. Tissue was screened for WMI by analyzing changes in GFAP (Rn01253033-m1) expression. Only H-I samples with 4- to
10-fold changes in GFAP expression versus controls were analyzed in
duplicate for HAS and Hyal transcripts using ABI 7300 System software. Gene expression is presented as relative quantity or fold change
versus control and calculated using the 2–ΔΔCt method. Statistical analysis
was performed on the ΔCt values for each gene.
Co-IP and Western blotting. For Co-IP(s), total protein extracts were
prepared in lysis buffer (1% TX-100, 10% glycerol, 1 mM β-glycerol-P,
150 mM NaCl, 10 mM NaF, 50 mM Tris, pH 7.4) supplemented with
complete protease inhibitor cocktail (MilliporeSigma) and complete
phosphatase inhibitor cocktail (Roche). Homogenates were centrifuged (15,000 g, 10 minutes). 500 μg of supernatant total protein lysate
was incubated with primary antibodies for 3 hours, followed by 1-hour
incubation with Protein A/G Sepharose beads (Invitrogen) at 4°C. Proteins were washed 3 times from the beads with lysis buffer before SDSPAGE. See complete unedited blots in the supplemental material.
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Antibodies were from the following sources: polyclonal rabbit
AKT (1:1,000; C67E7; catalog 4691), A20 (1:1,000; D13H3; catalog
5630), phospho-AKT T-308 (1:1,000; catalog 9275), phospho-AKT
S473 (1:1,000; catalog 9271), phospho-ERK1/2 (1:1,000; catalog 9102),
phospho-mTOR S2448 (1:1,000; D9C2; catalog 5536), phospho-GSK3β
Ser9 (1:500; 5B3; catalog 9323) and mouse monoclonal actin (1:4,000;
8H10D10; catalog 3700) antibodies were from Cell Signaling Technology; monoclonal mouse TRIF (1:200; E-7; catalog sc-514384),
TRAF6 (1:200; D10; catalog sc-8409), β-arrestin2 (1:200; H-9; catalog sc-13140), and rabbit polyclonal Pellino1/2 (1:200; H-105; catalog
sc-67025) antibodies were from Santa Cruz Biotechnology Inc. Equivalent protein amounts were analyzed by SDS-PAGE and transferred to an
Immobilon-FL membrane. Western blot detection employed IR700 or
IR800 or a special IR800-conjugated (incapable of detecting IgG) secondary antibody (Rockland Inc.). The pixel band intensity was analyzed
with the Odyssey Infrared system (Li-COR Biosciences).
ChIP assay. Mouse OPCs were grown in proliferation or differentiation medium (7) and treated with vehicle (PBS) or bHAf (500 nM),
followed by treatment with 1% formaldehyde (10 minutes; 37°C). Cells
were washed 3 times with ice-cold PBS containing a protease inhibitor cocktail (MilliporeSigma), lysed, and chromatin sheared to generate fragments of different sizes (14, 16). ChIP assays were performed
as described previously (16). For preclearing and pull-downs, we used
Protein A Sepharose (GE Healthcare) preblocked with yeast transfer
RNA and BSA. The antibodies used were rabbit anti-Olig2 (catalog
AB9610; Millipore), rabbit anti-Brg1 (D1Q7F; catalog 49360; Cell Signaling Technology), rabbit anti-FoxO3 (D19A7; catalog 12829; Cell Signaling Technology), and rabbit IgG (catalog 2729; Cell Signaling Technology). PCR was performed using Phusion Hot Start II High Fidelity
DNA Polymerase and the following primers: for MBP, forward primer
5′-AGAGGGAATGGACTTGCTGC, reverse primer 5′-GCGGTCGTTTGACAAAAGGT; for FoxO3, forward primer 5′-CGCAGTGGTGTGTTGTCTGA, reverse primer: 5′-CGGCAGCAGCACAAAGTTAT.
IHC. Antibodies used were as follows: mouse anti-MBP (1:500;
SMI-99; NE1019; Calbiochem), rat anti-MBP (1:500; MAB386;
EMD Millipore), mouse anti-GFAP (1:500; MAB360; EMD Millipore), mouse anti-O4 (1:500; from Steven Pfeiffer, University
of Connecticut Health Center, Farmington, Connecticut, USA),
rabbit anti-PDGFRα (1:500; from William Stallcup, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California,
USA), mouse anti-CNPase (1:500; SMI-91; Covance), mouse antiCASPR/paranodin (1:250; K65/35; NeuroMab), mouse anti–NF-H
(1:1,000; SMI312; BioLegend), rabbit anti–caspase-3 (1:200; 9662;
Cell Signaling Technology), mouse anti–FoxO3 C-terminus (1:100;
from Anne Brunet, Stanford University, Stanford, California, USA),
rabbit anti-FoxO3 (1:100; NB100-614; Novus Biologicals), goat
anti-Olig2 (1:100; AF2418; R&D Systems), and mouse anti-Olig2
(1:500; John Alberta, Dana-Farber Cancer Institute, Boston, Massachusetts, USA). HA was visualized with biotinylated HA-binding
protein (bHABP; 1:200; 385911; EMD Millipore). Selectivity of
HABP staining was confirmed with controls that excluded HABP or
secondary antibody (Supplemental Figure1A). Antigen retrieval was
employed for all antibodies (0.01 M citrate buffer pH 6.0, 85°C, 15
minutes). All corresponding secondary antibodies were from Jackson ImmunoResearch Laboratories Inc. Nuclei were counterstained
with DAPI (Invitrogen). No-primary control studies for all antibodies exhibited no specific staining.

Stereology. Cell counts of slice cultures were performed using a
Stereo Investigator stereology system (MBF Bioscience). Within the
10×-defined boundaries of the entire corpus callosum (defined by
DAPI staining), MBP+, Olig2+, and FoxO3+ double-labeled cells were
estimated using the optical fractionator probe (grid size, 300 × 400
μm; counting frame, 40 × 40 μm; z-depth, 40 μm) at 40× magnification in a minimum of 30 randomly selected WM fields per slice. Slice
thickness was measured at each counting site. Cell density (mm2)
was calculated by the formula (cell counts/[number of fields × counting frame area (mm2)]). Estimates of MBP-labeled cells were also
obtained using the meander scan function at 20×.
To estimate WM and cortex MBP area fractions, we assessed WMI
using an unbiased approach where lesions were not specifically selected. Montages were generated from frontal tissue sections fluorescently
stained for MBP. Montages were captured at 10× magnification, and MBP
staining was estimated using rolling-ball background subtraction with a
150-pixel radius. A pixel-intensity histogram was generated for each ROI
using ImageJ (NIH) and exported to R (R Project for Statistical Computing), and area fractions were obtained as described previously (17).
Human pathology. We studied 2 cohorts of human autopsy brains
with either chronic diffuse preterm WMI or chronic stages of WMI in
adult MS. Nine tissue blocks were retrospectively collected from archival
cases (formalin-fixed and paraffin-embedded). The 4 tissue blocks with
preterm WMI were previously described in Table 1 of ref. 17 and correspond to cases 7, 12, 13, and 17, with ages at birth of 32, 29, 25, and 26
weeks, respectively. Tissue blocks selected for the adult MS cohort had
chronic active or chronic remodeling (“shadow”) plaques, as previously
described (ref. 7 and see Supplemental Table 1).
Statistics. Statistical analysis was performed using Prism 7 statistical software (GraphPad Software). Comparisons between 2 groups were
made by 2-tailed Student’s t test. One-way ANOVA followed by Dunnett’s
multiple comparisons test was used to determine statistical significance
for more than 2 groups. P < 0.05 was considered statistically significant.
All experiments were repeated at least twice and performed with several
independent biological samples, as indicated in the figure legends.
Study approval. All animal procedures were approved by the
OHSU IACUC (protocol IP00000837) according to the NIH Guide for
the Care and Use of Laboratory Animals. All neonatal human WMI samples were obtained after full IRB review and approval from Children’s
and Women’s Hospital, University of British Columbia (Vancouver,
British Columbia, Canada) with the assistance of Glenda Hendson in
the Department of Pathology. All pathological diagnoses were independently confirmed by G. Hendson and Marjorie Grafe. All MS tissue
blocks were obtained with the assistance of C. Dirk Keene, Department of Pathology, University of Washington, Seattle, Washington,
USA. Tissues were obtained with the approval of the human subject
committee of the University of Washington.
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